S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Tekla Life Sciences Investors (HQL)
Chart Events
Performance Outlook
| Previous Close | 14.69 |
| Open | 14.86 |
| Bid | 14.69 x 800 |
| Ask | 15.15 x 800 |
| Day's Range | 14.36 - 14.84 |
| 52 Week Range | 13.86 - 22.70 |
| Volume | |
| Avg. Volume | 75,481 |
| Market Cap | 362.132M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | 5.61 |
| EPS (TTM) | 2.62 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.56 (10.83%) |
| Ex-Dividend Date | Feb 24, 2022 |
| 1y Target Est | N/A |
- Business Wire
Tekla Life Sciences Investors Declares Distribution
BOSTON, May 17, 2022--On May 17, 2022, Tekla Life Sciences Investors declared a distribution of $0.35 per share. The record date for the distribution is May 27, 2022 and the payable date is June 30, 2022. The Fund will trade ex-distribution on May 26, 2022.
- Business Wire
Tekla Life Sciences Investors Paid Distribution
BOSTON, March 31, 2022--On March 31, 2022, Tekla Life Sciences Investors paid a distribution of $0.39 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains and return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio s
- Business Wire
Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
BOSTON, March 22, 2022--Tekla Life Sciences Investors (the "Fund") announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2022. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2023. The Board autho
